Introduction
Materials and Methods
Patients
Main Development Cohort
Validation Cohort
Database
Surgery
Bile Leakage Definition
Study Design
Biliary Leakage Risk Score (BLRS)
Statistical Analysis
Ethical Aspects
Results
Patient’s Characteristics and Surgical Procedures
Whole cohort n = 844 | Group 1 (without POBL) n = 711 | Group 2 (with POBL) n = 133 | p-value | |||||
---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | |||
Gender | ||||||||
Male | 553 | 65.5% | 463 | 65.1% | 90 | 67.7% | 0.570 | |
Female | 291 | 34.5% | 248 | 34.9% | 43 | 32.3% | ||
Age [years] | 63.5 ± 11.9 | 63.0 ± 12.0 | 66.1 ± 11.1 | 0.006 | ||||
Body mass index [kg/m2] | 26.8 ± 5.5 | 26.8 ± 5.4 | 26.9 ± 5.7 | 0.778 | ||||
ASA Classification | ASA I | 13 | 1.5% | 13 | 1.8% | 0 | 0% | 0362 |
ASA II | 291 | 34.5% | 246 | 34.6% | 45 | 33.8% | ||
ASA III | 535 | 63.4% | 447 | 62.9% | 88 | 66.2% | ||
ASA IV | 3 | 0.4% | 3 | 0.4% | 0 | 0% | ||
Diabetes mellitus | 224 | 26.5% | 185 | 26.0% | 39 | 29.3% | 0.428 | |
Renal insufficiency | 115 | 13.6% | 95 | 13.4% | 20 | 15.0% | 0.605 | |
Smoking | 116 | 13.7% | 100 | 14.1% | 16 | 12.0% | 0.532 | |
Alcohol abuse | 46 | 5.5% | 44 | 6.2% | 2 | 1.5% | 0.029 | |
Aspirine intake | 101 | 12.0% | 81 | 11.4% | 20 | 15.0% | 0.235 | |
CASH | 46 | 5.5% | 35 | 4.9% | 11 | 8.3% | 0.118 | |
Liver fibrosis or cirhosis | 429 | 50.8% | 352 | 49.5% | 77 | 57.9% | 0.076 | |
Preceeding liver resection | 218 | 25.8% | 187 | 26.3% | 31 | 23.3% | 0.469 | |
Neoadjuvant chemotherapy | 154 | 18.3% | 135 | 19.0% | 19 | 14.3% | 0.198 | |
Neoadjuvant antibody treatment | 11 | 1.3% | 10 | 1.4% | 1 | 0.8% | 0.541 | |
Neoadjuvante combined chemo- and antibody therapy | 187 | 22.2% | 157 | 22.1% | 30 | 22.6% | 0.904 | |
Monotherapy FOLFOX | 48 | 5.7% | 39 | 5.5% | 9 | 6.8% | 0.558 | |
Monotherapy FOLFIRI | 12 | 1.4% | 12 | 1.7% | 0 | 0% | 0.131 | |
Monotherapy 5-FU | 8 | 1.0% | 6 | 0.8% | 2 | 1.5% | 0.471 | |
Monotherapy FOLFOXIRI | 33 | 3.9% | 32 | 4.5% | 1 | 0.8% | 0.041 | |
Combined treatment FOLFOX und cetuximab | 25 | 3.0% | 17 | 2.4% | 8 | 6.0% | 0.024 | |
Combined treatment FOLFIRI und cetuximab | 33 | 3.9% | 28 | 3.9% | 5 | 3.8% | 0.922 | |
Combined treatment FOLFIRI und Bevacizumab | 14 | 1.7% | 12 | 1.7% | 2 | 1.5% | 0.879 | |
Preoperative interventions | 160 | 19.0% | 124 | 17.4% | 36 | 27.1% | 0.009 | |
PVE TACE ERCP + Stent/ PTCD | 115 | 13.6% | 93 | 13.1% | 22 | 16.5% | 0.003 | |
18 | 2.1% | 13 | 1.8% | 5 | 3.8% | |||
19 | 2.3% | 11 | 1.6% | 8 | 6.0% | |||
Diagnosis | ||||||||
Colorectal liver metastases | 417 | 49.4% | 358 | 50.4% | 59 | 44.4% | 0.205 | |
Hepatocellular carcinoma | 153 | 18.1% | 135 | 19.0% | 18 | 13.5% | 0.134 | |
Cholangiocarcinoma (overall) | 175 | 20.7% | 126 | 17.7% | 49 | 36.8% | < 0.001 | |
Gall bladder carcinoma Intrahepatic cholangiocarcinoma Klatskin tumor | 23 | 2.7% | 18 | 2.5% | 5 | 3.8% | 0.425 | |
109 | 12.9% | 84 | 11.8% | 25 | 18.8% | 0.028 | ||
43 | 5.1% | 24 | 3.4% | 19 | 14.3% | < 0.001 | ||
Neuroendocrine liver metastases | 32 | 3.8% | 31 | 4.4% | 1 | 0.8% | 0.046 | |
NCNN liver metastases | 65 | 7.7% | 60 | 8.4% | 5 | 3.8% | 0.063 | |
Surgical procedures | ||||||||
Major resection | 347 | 41.1% | 262 | 36.9% | 85 | 63.9% | < 0.001 | |
ALPPS | 45 | 5.3% | 36 | 5.1% | 9 | 6.8% | 0.422 | |
Minor resection (overall) | 435 | 51.5% | 397 | 55.8% | 38 | 28.6% | < 0.001 | |
Minor anatomical resection | 176 | 20.9% | 159 | 22.4% | 17 | 12.8% | 0.013 | |
Number of segments in anatomical minor resections | 2.05 ± 1.99 | 1.89 ± 1.95 | 2.94 ± 1.98 | < 0.001 | ||||
Minor non-anatomical resection | 259 | 30.7% | 238 | 33.5% | 21 | 15.8% | < 0.001 | |
Number of segments in non-anatomical minor resections | 2.21 ± 1.68 | 2.24 ± 1.72 | 1.95 ± 1.07 | 0.238 | ||||
Operating time (min) | 265.8 ± 133.1 | 252.4 ± 126.0 | 337.5 ± 146.7 | 0.012 | ||||
Pringle clamping | 189 | 22.4% | 156 | 21.9% | 33 | 24.8% | 0.466 | |
VCI clamping | 111 | 13.2% | 82 | 11.5% | 29 | 21.8% | 0.001 | |
VCI resection | 50 | 5.9% | 36 | 5.1% | 14 | 10.5% | 0.014 | |
Biliodigestive anastomosis | 100 | 11.9% | 62 | 8.7% | 38 | 28.6% | < 0.001 | |
Portal vein reconstruction | 22 | 2.6% | 11 | 1.6% | 11 | 8.3% | < 0.001 | |
Hepatic artery reconstruction | 8 | 1.0% | 4 | 0.6% | 4 | 3.0% | 0.008 | |
Lymph node dissection | 264 | 31.3% | 213 | 30.0% | 51 | 38.4% | 0.055 | |
Intraoperative transfusion of PRBC | 0.78 ± 1.75 | 0.68 ± 1.63 | 1.32 ± 2.20 | < 0.001 | ||||
Intraoperative transfusion of platelets | 0.04 ± 0.28 | 0.03 ± 0.23 | 0.10 ± 0.48 | 0.049 | ||||
Intraoperative transfusion of FFP | 1.30 ± 2.77 | 1.14 ± 2.62 | 2.14 ± 3.36 | < 0.001 |
Postoperative Outcome
Whole cohort n = 844 | Group 1 (without POBL) n = 711 | Group 2 (with POBL) n = 133 | p-value | |||||
---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | |||
Surgical revision | Excluding ISGL Grade C leakage | 99 | 11.7% | 67 | 9.4% | 32 | 24.1% | < 0.001 |
Including ISGL Grade C leakage | 125 | 14.8% | 67% | 9.4% | 58 | 43.6% | < 0.001 | |
ICU stay [days] | Median 1 IQR 0.0–4.0 | Median 1 IQR 1.0–3.0 | Median 4 IQR 2.0–12.75 | < 0.001 | ||||
Hospital stay [days] | Median 13 IQR 9.0–23.0 | Median 12 IQR 9.0–12.0 | Median 26 IQR 16.25–45.0 | < 0.001 | ||||
30-day mortality | 36 | 4.3% | 24 | 3.4% | 12 | 9.0% | 0.003 | |
Postoperative occurrence of septical complications | 44 | 5.2% | 25 | 3.5% | 19 | 14.3% | < 0.001 | |
Complications according to Clavien | ||||||||
I | 54 | 6.4% | 45 | 6.3% | 9 | 6.8% | < 0.001 | |
II | 71 | 8.4% | 56 | 7.9% | 15 | 11.3% | ||
III | 149 | 17.7% | 81 | 11.4% | 68 | 51.1% | ||
IV | 40 | 4.7% | 18 | 2.5% | 22 | 16.5% | ||
V | 50 | 5.9% | 31 | 4.4% | 19 | 14.3% | ||
Number of complications | ||||||||
1 | 145 | 17.2% | 120 | 16.9% | 25 | 18.8% | < 0.001 | |
1–3 | 128 | 15.2% | 80 | 11.3% | 48 | 36.1% | ||
> 3 | 91 | 10.8% | 31 | 4.4% | 60 | 45.1% |
Comparative Analysis and Univariate Analyses for Postoperative Bile Leakage
Patients’ Characteristics, Diagnoses, and Surgical Procedures
Postoperative Outcome
Multivariate Analysis for Postoperative Bile Leakage (POBL) and Biliary Leakage Risk Score (BLRS)
Parameter | Regression coefficient | Odd’s ratio (95% CI) | p-value |
---|---|---|---|
Age | 0.026 | 1.026 (1.007–1.047) | 0.008 |
Major resection | 0.841 | 2.320 (1.489–3.614) | < 0.001 |
Combined treatment FOLFOX und Cetuximab | 1.253 | 3.500 (1.393–8.794) | 0.008 |
Operating time | 0.004 | 1.004 (1.003–1.006) | < 0.001 |
Constant | − 5.039 | 0.006 | < 0.001 |
BLRS model | BLRS | Risk according to BLRS (in %) | n = 844 | POBL | Odd’s ratio (95% CI) | p-value | |
---|---|---|---|---|---|---|---|
n | % | ||||||
2-stage (Binary) | < 0.149 | < 15% | 518 | 39 | 7.5% | ||
≥ 0.149 | > 15% | 326 | 94 | 28.8% | 4.976 (3.319–7.460) | < 0.001 |
Validation of the Biliary Risk Score
BLRS model | BLRS | Risk according to BLRS (in %) | n = 142 | POBL | Odd’s ratio (95% CI) | p-value | |
---|---|---|---|---|---|---|---|
n | % | ||||||
2-stage (Binary) | < 0.149 | < 15% | 98 | 7 | 7.1% | ||
≥ 0.149 | > 15% | 44 | 15 | 34.1% | 6.724 (2.499–18.091) | < 0.001 |